share_log

HOOKIPA Pharma | 3: Initial statement of beneficial ownership of securities-Officer Winderlich Mark

HOOKIPA Pharma | 3: Initial statement of beneficial ownership of securities

HOOKIPA Pharma | 3：首次持股聲明
美股sec公告 ·  04/12 04:21
牛牛AI助理已提取核心訊息
Mark Winderlich, the Chief Development Officer of HOOKIPA Pharma Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The filing, dated April 1, 2024, indicates that Winderlich does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Reinhard Kandera, was completed on April 11, 2024. This standard disclosure is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies.
Mark Winderlich, the Chief Development Officer of HOOKIPA Pharma Inc., has filed an Initial Statement of Beneficial Ownership of Securities with the SEC, as per Form 3 requirements. The filing, dated April 1, 2024, indicates that Winderlich does not beneficially own any non-derivative or derivative securities of the company. The form, signed by attorney-in-fact Reinhard Kandera, was completed on April 11, 2024. This standard disclosure is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine filing for officers of publicly traded companies.
根據表格3的要求，HOOKIPA Pharma Inc. 的首席開發官馬克·溫德利希已向美國證券交易委員會提交了初步的證券實益所有權聲明。該文件日期爲2024年4月1日，表明溫德利希不以實益方式擁有該公司的任何非衍生或衍生證券。該表格由事實上的律師萊因哈德·坎德拉簽署，於2024年4月11日完成。該標準披露符合1934年《證券交易法》第16（a）條，是上市公司高管的例行申報。
根據表格3的要求，HOOKIPA Pharma Inc. 的首席開發官馬克·溫德利希已向美國證券交易委員會提交了初步的證券實益所有權聲明。該文件日期爲2024年4月1日，表明溫德利希不以實益方式擁有該公司的任何非衍生或衍生證券。該表格由事實上的律師萊因哈德·坎德拉簽署，於2024年4月11日完成。該標準披露符合1934年《證券交易法》第16（a）條，是上市公司高管的例行申報。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。